Cecilia Taverna1,2, Martina Baněčková3, Monica Lorenzon4, Annarita Palomba5, Alessandro Franchi6, Alena Skalova3, Abbas Agaimy1. 1. Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital, Erlangen, Germany. 2. Department of Laboratory Medicine, Unit of Anatomical Pathology, Pisa University Hospital, Pisa, Italy. 3. Department of Pathology, Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic. 4. The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. 5. Unit of Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy. 6. Department of Translational Research, School of Medicine, University of Pisa, Pisa, Italy.
Abstract
AIMS: Secretory carcinoma (SC) (synonym: mammary analogue secretory carcinoma) is a low-grade salivary gland tumour that occurs in both major and minor salivary glands. SC is known for its wide morphological, architectural and immunohistochemical spectrum, which overlaps with those of several salivary gland neoplasms, including acinic cell carcinoma (AciCC) and intercalated duct-type intraductal carcinoma (IDC) in major salivary glands, and polymorphous adenocarcinoma (PAC) in minor salivary glands. These tumours share with SC some morphological features and SOX10 immunoreactivity; also, with the exception of AciCC, they all coexpress S100 and mammaglobin. METHODS AND RESULTS: We compared MUC4 and mammaglobin expression in 125 salivary gland carcinomas (54 genetically confirmed SCs, 20 AciCCs, 21 PACs, and 30 IDCs) to evaluate the potential of these two markers to differentiate these entities. Moderate to strong diffuse MUC4 positivity was detected in 49 SCs (90.7%), as compared with none of the IDCs and PACs. In contrast, mammaglobin was frequently expressed in SCs (30 of 36 cases; 83.3%), IDCs (24/28; 85.7%), and PACs (7/19; 36.8%). Two of three high-grade SCs lost MUC4 expression in the high-grade tumour component. No significant correlation was found between MUC4 expression and the fusion variant in SC (ETV6-NTRK versus non-ETV6-NTRK). CONCLUSION: The results of our study identify MUC4 as a sensitive (90.7%) and specific (100%) marker for SC, with high positive (100%) and negative (93.4%) predictive values. Thus, MUC4 may be used as a surrogate for SC in limited biopsy material and in cases with equivocal morphology.
AIMS: Secretory carcinoma (SC) (synonym: mammary analogue secretory carcinoma) is a low-grade salivary gland tumour that occurs in both major and minor salivary glands. SC is known for its wide morphological, architectural and immunohistochemical spectrum, which overlaps with those of several salivary gland neoplasms, including acinic cell carcinoma (AciCC) and intercalated duct-type intraductal carcinoma (IDC) in major salivary glands, and polymorphous adenocarcinoma (PAC) in minor salivary glands. These tumours share with SC some morphological features and SOX10 immunoreactivity; also, with the exception of AciCC, they all coexpress S100 and mammaglobin. METHODS AND RESULTS: We compared MUC4 and mammaglobin expression in 125 salivary gland carcinomas (54 genetically confirmed SCs, 20 AciCCs, 21 PACs, and 30 IDCs) to evaluate the potential of these two markers to differentiate these entities. Moderate to strong diffuse MUC4 positivity was detected in 49 SCs (90.7%), as compared with none of the IDCs and PACs. In contrast, mammaglobin was frequently expressed in SCs (30 of 36 cases; 83.3%), IDCs (24/28; 85.7%), and PACs (7/19; 36.8%). Two of three high-grade SCs lost MUC4 expression in the high-grade tumour component. No significant correlation was found between MUC4 expression and the fusion variant in SC (ETV6-NTRK versus non-ETV6-NTRK). CONCLUSION: The results of our study identify MUC4 as a sensitive (90.7%) and specific (100%) marker for SC, with high positive (100%) and negative (93.4%) predictive values. Thus, MUC4 may be used as a surrogate for SC in limited biopsy material and in cases with equivocal morphology.
Authors: Sandra Gjorgova Gjeorgjievski; Karen Fritchie; Judith Jebastin Thangaiah; Andrew L Folpe; Nasir Ud Din Journal: Head Neck Pathol Date: 2021-09-24
Authors: Kartik Viswanathan; Peter M Sadow; Zahra Maleki; Michiya Nishino; Zubair W Baloch; Todd E Abbott; Rema Rao; William C Faquin Journal: Cancer Cytopathol Date: 2021-10-01 Impact factor: 4.264
Authors: Nicolas Macagno; Pierre Sohier; Thibault Kervarrec; Daniel Pissaloux; Marie-Laure Jullie; Bernard Cribier; Maxime Battistella Journal: Cancers (Basel) Date: 2022-01-18 Impact factor: 6.639
Authors: Austin B Wiles; Matthew Gabrielson; Zubair W Baloch; William C Faquin; Vickie Y Jo; Fabiano Callegari; Ivana Kholova; Sharon Song; Barbara A Centeno; Syed Z Ali; Satu Tommola; Guido Fadda; Gianluigi Petrone; He Wang; Esther D Rossi; Liron Pantanowitz; Zahra Maleki Journal: Cancer Cytopathol Date: 2022-04-06 Impact factor: 4.264